Skip to content
← Full study record

NCT04914897 · MORE INFO

Limitations, agreements, and source contact

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) · Source last updated 2025-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The study was terminated based on strategic sponsor decision not driven by any safety concerns.
point Of Contact
email
Contact-US@sanofi.com
organization
Sanofi aventis recherche & développement
phone
800-633-1610
phone Ext
6#
title
Trial Transparency Team
Complete source fields
certain Agreement
other Details
The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The study was terminated based on strategic sponsor decision not driven by any safety concerns.
point Of Contact
email
Contact-US@sanofi.com
organization
Sanofi aventis recherche & développement
phone
800-633-1610
phone Ext
6#
title
Trial Transparency Team

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice